Home » Newsletters » BioWorld Science

BioWorld Science

Feb. 18, 2013

View Archived Issues

International trial of rhNGF begins in the treatment of neurotrophic keratitis

Roche presents potential predictivity of preclinical cancer models

177Lu-J-591 shows promising antitumor activity at the MTD of 70 mCi/m2

Shin Nippon Biomedical Laboratories and Kyoto University enter agreement

Mylan enters generic insulin agreement with Biocon

Antitumor activity demonstrated for TRAIL-inducing compound TIC-10

Dako launches nontoxic FISH assay for cancer diagnosis in U.S.

Third Rock Ventures launches new company with a focus on cancer immunotherapy

Emory University and Health Research patent new TAK1 inhibitors

Novartis presents final results of a phase II study of dovitinib in urothelial cancer

FDA grants orphan drug status to OSE-2101

GlaxoSmithKline presents novel Lp-PLA2 inhibitors

Nerviano Medical Sciences divulges new protein kinase inhibitors

Novel c-Kit inhibitors presented by AB Science

Researchers at Allergan synthesize new alpha-adrenoceptor agonists

Phase II results for linsitinib in mCRPC presented

Livalo OD tablets approved in Japan for hypercholesteremia

FDA advisory committee recommends approval of contrast agent Dotarem

FDA accepts Oralair BLA for review

Piromelatine shows promise in phase II insomnia trial

Verastem compounds target cancer stem cells

FDA approves Zortress in new indication

Scientists at Grunenthal prepare novel TRPV1 ligands

Lilly and QIAGEN to collaborate on companion diagnostics

FDA grants priority review to dolutegravir NDA

Phase II trial of Cogane in Parkinson's disease misses endpoints

FDA approves Argus II Retinal Prosthesis System for patients with advanced retinitis pigmentosa

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 3, 2026.
ASCO 2026: A revolution in pancreatic cancer
BioWorld
At the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, Revolution Medicines Inc. followed up its stellar top-line data with the details from the...
News in brief
BioWorld Asia
BioWorld Asia briefs for June 2, 2026
EASL 2026: Emerging liver disease targets to watch
BioWorld
At the recently concluded European Association for the Study of the Liver meeting, presentations underscored how increasingly granular insights into liver...
ASCO 2026: PD-(L)1 x VEGF bispecifics fight it out
BioWorld
Multiple companies are chasing Akeso Inc. and Summit Therapeutics Inc. in the battle to potentially dethrone Keytruda (pembrolizumab, Merck & Co. Inc.) as the top...